Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis.
Novin NezamololamaErika L CrowleyMelinda J GooderhamKim A PappPublished in: Expert opinion on investigational drugs (2020)
Evidence supports clinical efficacy, improved pruritus and an acceptable safety profile, making abrocitinib a viable alternative to conventional AD therapies. Pivotal phase III trials included subjects aged 12 years and above, providing a new mechanism of action for future treatment of adolescent and adult AD. Further investigations are required to have a thorough understanding of abrocitinib in the treatment of AD.